课题基金 / 基金详情

IV CYT-103-90Y IN REFRACTORY B72.3 REACTIVE CARCINOMA

IV CYT-103-90Y IN REFRACTORY B72.3 REACTIVE CARCINOMA
IV CYT-103-90Y 治疗难治性 B72.3 反应性癌
批准号：
3862719
负责人：
STEVEN T. ROSEN
金额：
$0.0万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3862719
关键词：
adenocarcinoma dosage drug adverse effect drug tolerance human subject human therapy evaluation immunoconjugates immunotherapy monoclonal antibody neoplasm /cancer immunotherapy neoplasm /cancer relapse /recurrence radiotracer

项目摘要

项目成果

STEVEN T. ROSEN的其他基金

相似基金

相关文献

中文摘要
翻译
本研究评估生物分布、潜在毒性和益处
英文摘要
This study evaluates biodistribution potential toxicities and benefits of increasing doses of a radiolabeled (90y) monoclonal antibody (B72.3) for therapy of patients with relapsed/or refractory adenocarcinomas which are shown to be TAG-72 (antigen which B72.3 recognizes) positive. The goal is to define the maximum tolerated dose in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF LYMPHOCYTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES
TREATMENT OF LYMPHOCYTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES
TREATMENT OF OVARIAN CANCER WITH MONOCLONAL ANTIBODIES
RADIOLABELED MONOCLONAL ANTIBODY T101 TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (HUM
海外基金